Creon: Shortages of pancreatic enzyme replacement therapy are causing “worry and stress”

An ongoing shortage of the pancreatic enzyme replacement therapy (PERT) Creon in the UK is causing “significant worry and stress” for patients, doctors, and pharmacists, representative groups have warned.In May this year the Department of Health and Social Care issued a national patient safety alert about shortages of the drug, which is used to treat pancreatic exocrine insufficiency in patients with cystic fibrosis, pancreatic cancer, and pancreatitis. It said the disruption to supply was due to limited availability of active pharmaceutical ingredients and manufacturing constraints to produce the volumes needed to meet demand.1With no clinical alternative available to those affected, clinicians and charities have warned that patients are being left at risk.In an update on 16 July 2024 the Cystic Fibrosis Trust said, “This has caused significant worry and stress for those affected who have sometimes needed to travel to multiple pharmacies to find Creon. We’ve been really concerned to…
Read Original Article: Creon: Shortages of pancreatic enzyme replacement therapy are causing “worry and stress” »